Candel Therapeutics Files 8-K

Ticker: CADL · Form: 8-K · Filed: Feb 25, 2025 · CIK: 1841387

Sentiment: neutral

Topics: 8-K, corporate-disclosure, financials

TL;DR

Candel Therapeutics filed an 8-K on Feb 25, 2025, covering Reg FD, other events, and financials.

AI Summary

Candel Therapeutics, Inc. filed an 8-K on February 25, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Needham, MA.

Why It Matters

This 8-K filing provides updates on Candel Therapeutics' corporate activities and financial reporting, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Candel Therapeutics?

The primary purpose is to report on Regulation FD disclosures, other events, and financial statements and exhibits as of February 25, 2025.

When was the earliest event reported in this filing?

The earliest event reported was on February 25, 2025.

In which state is Candel Therapeutics, Inc. incorporated?

Candel Therapeutics, Inc. is incorporated in Delaware.

What is the business address of Candel Therapeutics, Inc.?

The business address is 117 Kendrick St., Suite 450, Needham, MA 02494.

What is the SEC file number for Candel Therapeutics, Inc.?

The SEC file number is 001-40629.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 regarding Candel Therapeutics, Inc. (CADL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing